Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of a fixed-dose, daily
regimen of orally administered PCI-32765 combined with ofatumumab in subjects with
relapsed/refractory CLL/SLL and related diseases